ResearcherTUM KlinikumActive in the last 2 years
Aristeidis Papargyriou
Matched on ORCID iD 0000-0002-2577-4737; OpenAlex author ID A5025024466. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 64
2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 4 papers
Papers 7
- A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
- Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41551-024-01273-9↗
- The Biology in the Pattern: Metastatic Organotropism and Clinical Outcome Depend on DNA Damage Response and Immune Interactions in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1085↗
- Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Co-author DOI 10.1172/jci.insight.169105↗
- A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
- Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Co-author DOI 10.1053/j.gastro.2020.09.010↗
- Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
Closest collaborators
The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Maximilian Reichert · 7 shared papers, 2020–2025 · strength 1.33
- Paper The Biology in the Pattern: Metastatic Organotropism and Clinical Outcome Depend on DNA Damage Response and Immune Inte… DOI 10.1158/0008-5472.can-25-1085↗
- Paper Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. DOI 10.1172/jci.insight.169105↗
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7↗
- Roland Rad · 6 shared papers, 2020–2025 · strength 0.79
- Paper Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. DOI 10.1172/jci.insight.169105↗
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7↗
- Paper Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal aden… DOI 10.1038/s41551-024-01273-9↗
- Roland Michael Schmid · 5 shared papers, 2020–2025 · strength 0.65
- Paper Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. DOI 10.1172/jci.insight.169105↗
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7↗
- Paper Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal aden… DOI 10.1038/s41551-024-01273-9↗
- Günter Schneider · 5 shared papers, 2020–2025 · strength 0.63
- Paper Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. DOI 10.1172/jci.insight.169105↗
- Paper Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal aden… DOI 10.1038/s41551-024-01273-9↗
- Paper A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. DOI 10.1002/advs.202307695↗
- Dieter Saur · 5 shared papers, 2020–2025 · strength 0.63
- Paper Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. DOI 10.1172/jci.insight.169105↗
- Paper Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal aden… DOI 10.1038/s41551-024-01273-9↗
- Paper A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. DOI 10.1002/advs.202307695↗
- Felix Orben · 3 shared papers, 2020–2025 · strength 0.38
- Paper Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. DOI 10.1172/jci.insight.169105↗
- Paper A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. DOI 10.1002/advs.202307695↗
- Paper Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. DOI 10.1172/jci.insight.137809↗
- Stefanie Bärthel · 2 shared papers, 2025 · strength 0.32
- Paper Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. DOI 10.1172/jci.insight.169105↗
- Paper Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal aden… DOI 10.1038/s41551-024-01273-9↗
- Katja Peschke · 3 shared papers, 2020–2025 · strength 0.32
- Paper Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal aden… DOI 10.1038/s41551-024-01273-9↗
- Paper Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. DOI 10.1053/j.gastro.2020.09.010↗
- Paper Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. DOI 10.1172/jci.insight.137809↗
- Sebastian Mueller · 2 shared papers, 2025 · strength 0.32
- Paper A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic canc… DOI 10.1038/s41467-025-56493-7↗
- Paper Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal aden… DOI 10.1038/s41551-024-01273-9↗
- Bernhard Küster · 2 shared papers, 2024–2025 · strength 0.31
- Christian Schneeweis · 2 shared papers, 2024–2025 · strength 0.30
- H. Carlo Maurer · 2 shared papers, 2021–2025 · strength 0.27
- Hana Algül · 2 shared papers, 2020–2025 · strength 0.23
- Georgios A. Kaissis · 2 shared papers, 2020–2025 · strength 0.22
- Irina Heid · 2 shared papers, 2020–2025 · strength 0.22
- Sebastian Lange · 2 shared papers, 2020–2025 · strength 0.22
- Rickmer Braren · 2 shared papers, 2020–2025 · strength 0.22
- Matthias Wirth · 2 shared papers, 2020–2024 · strength 0.21
- Katja Wittenzellner · 1 shared paper, 2025 · strength 0.17
- Daniele Lucarelli · 1 shared paper, 2025 · strength 0.17
- Helmut Friess · 1 shared paper, 2025 · strength 0.17
- İhsan Ekin Demir · 1 shared paper, 2025 · strength 0.17
- Karin Feldmann · 2 shared papers, 2020–2021 · strength 0.17
- Wilko Weichert · 2 shared papers, 2020–2021 · strength 0.17
- Zahra Dantes · 2 shared papers, 2020–2021 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.